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Rhein (4, 5-dihydroxyanthraquinone-2-carboxylic acid) is a lipophilic anthraquinone extensively found in medicinal herbs, such
as Rheum palmatum L., Cassia tora L., Polygonum multiflorum Thunb., and Aloe barbadensis Miller, which have been used
medicinally inChina formore than 1,000 years. Its biological activities related to humanhealth are being explored actively. Emerging
evidence suggests that rhein has many pharmacological effects, including hepatoprotective, nephroprotective, anti-inflammatory,
antioxidant, anticancer, and antimicrobial activities. The present review provides a comprehensive summary and analysis of the
pharmacological properties of rhein, supporting the potential uses of rhein as a medicinal agent.
1. Introduction
Rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid,
Figure 1) is a lipophilic anthraquinone extensively found in
medicinal herbs Rheum palmatum L., Cassia tora L., Polygo-
num multiflorumThunb. and Aloe barbadensisMiller, and so
on, which have been usedmedicinally in China formore than
1,000 years. Diarrhea, the most common side effect, is well
tolerated in humans. Rhein exhibits linear pharmacokinetics
between 50 and 200mg [1] and has many pharmacological
effects, including hepatoprotective, nephroprotective, anti-
inflammatory, antioxidant, anticancer, and antimicrobial
activities (summarized in Table 1). These pharmacological
effects lay the foundation for the treatment of hepatic
disease [2], osteoarthritis [3], diabetes [4], atherosclerosis
[5], and various cancers, such as nasopharyngeal carcinoma
[6], tongue cancer [7], hepatocellular carcinoma [8], and
lung cancer [9]. The aim of the present review was to give a
comprehensive summary and analysis of the pharmacological
properties of rhein, supporting the potential uses of rhein as
a medicinal agent.
2. Pharmacology
2.1. Hepatoprotective Activity. Rhein has been shown tomod-
ulate cytochrome P450 (CYP) enzymes in rat liver micro-
somes. For example, rhein significantly inhibited CYP2E1;
inhibition constant (Ki) = 10 𝜇m (mixed); CYP2C9 and
CYP3A were also inhibited evidently; Ki = 38 𝜇m (mixed)
andKi = 30 𝜇m (mixed), respectively; but rhein revealed only
mild inhibitory effects on CYP1A2 (Ki = 62𝜇m, uncompeti-
tive) and CYP2D6 (Ki = 74𝜇m, mixed) [10].
In hepatitis B virus-transgenic mice with nonalcoholic
steatohepatitis induced by a high-fat (HF) diet, rhein was
found to attenuate the serum levels of total cholesterol,
triglyceride, and fasting plasma glucose, ameliorating glucose
and lipid metabolism [11]. Oral administration of rhein
significantly accelerated energy expenditure and decreased
the levels of cholesterol and liver triglyceride. It lowered body
weight, the expression of the lipogenic enzyme sterol regu-
latory element-binding protein-1c (SREBP-1c) and its target
genes in liver, and the transcriptional activity of SREBP-1c
through its upstream regulator, liver X receptor (LXR). Rhein
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Figure 1: Chemical structure of rhein.
also improved insulin resistance and hepatic steatosis and
normalized alanine aminotransferase (ALT) levels inHFdiet-
induced obese mice. Moreover, rhein regulated the T helpers
Th1/Th2 responses by inhibition of T-box expressed in T-
cells (T-bet) expression and enhancement of GATA-binding
protein-3 expression through increased signal transducer and
activator of transcription 6 phosphorylation [12].
Fibrosis, characterized by extracellular matrix accumula-
tion and disruption of normal tissue structure, is a common
cause of chronic failure of many organs [13]. The recent
evidence supports rhein as an antifibrotic agent in hep-
atic disorders. In carbon tetrachloride/ethanol-induced liver
fibrosis rats, rhein downregulated the levels of serum ALT,
hyalauronic acid, procollagen type III, and liver malondi-
aldehyde (MDA), upregulated the liver superoxide dismutase
(SOD) level, and inhibited the expression of transforming
growth factor beta 1 (TGF-𝛽1) and alpha-smooth muscle
actin (𝛼-SMA), the collagen staining positive area and the
grade of fibrosis in the liver [2]. Furthermore, rheinmarkedly
improved histological changes of fibrosis and attenuated the
expression of 𝛼-SMA and TGF-𝛽1 in the liver, suggesting its
protective effect from hepatocyte injury and hepatic fibrosis
[14].
2.2. Nephroprotective Activity. Several researches have demo-
nstrated the nephroprotective property of rhein both in vivo
and in vitro. In Sprague-Dawley rats with immune globulin
anephropathy (IgAN), rhein enhanced the expression of
intestinal epithelial tight junction proteins zona occludens
protein-1 and occludin, repaired damaged tight junctions,
and protected the intestinal barrier [15]. Oral administration
of rhein (150mg/kg/d) evidently ameliorated renal interstitial
fibrotic lesions and attenuated the expression of 𝛼-SMA and
deposition of fibronectin (FN) in mice with renal interstitial
fibrosis induced by unilateral ureteral obstruction. Rhein
also suppressed TGF-𝛽1 and its type I receptor expression in
obstructed kidneys. In vitro, rhein abolished the 𝛼-SMA and
FN expression in rat kidney interstitial fibroblasts cells (NRK-
49F) induced by TGF-𝛽1, suggesting that rhein is a potent
inhibitor of renal interstitial fibrosis [16].
Rhein markedly ameliorated the glomerular hypertro-
phy, mesangial expansion, excessive extracellular matrix,
and renal capsule dilation in IgAN rats. Additionally,
rhein administration evidently decreased IgA deposition in
glomerulus, the volume of urinary red blood cells, 24-h
urinary protein excretion, and the expression of upregulated
FN and 𝛼-SMA in renal tissue [17]. In chronic allograft
nephropathy rat models, rhein improved renal function
through reductions of renal fibrosis and interstitial inflam-
mation and increases of bone morphogenetic protein 7 and
hepatic growth factor levels. Furthermore, both FN and
collagen IV were reduced in the extracellular matrix [18].
Rhein was capable of protecting against renal injury
progression and ameliorating pathological changes by regu-
lation of the activities of nuclear factor-kappa B (NF-𝜅B) and
caspase-3 in the early phase of glomerulosclerosis induced by
both unilateral nephrectomy and injection with adriamycin
into caudal vein in rats. One of the possible molecular
mechanisms by which rhein alleviated renal tissue cell apop-
tosis in glomerulosclerosis is that caspase-3 expression in
kidney is downregulated [19]. Furthermore, rhein inhibited
the hypertrophy of renal proximal tubular epithelial cells
induced by high glucose (30mM) and angiotensin II (10−7M)
in rats through significantly decreasing increased cell size,
3H-leucine incorporation, and cellular protein content [20].
2.3. Chondroprotective Activity. There has been a large
amount of research on the effects of rhein on osteoarthritis
(OA) chondrocytes and tissue separated from human or
other animals. Interleukin-1𝛽 (IL-1𝛽) plays a fundamen-
tal role in OA pathophysiology and cartilage destruction
[3]. Several cells in articular joint tissue produce IL-1𝛽,
such as macrophages, synovial cells, and chondrocytes. This
cytokine contributes to degeneration of articular cartilage
by stimulating the cells to produce proteolytic enzymes
and by decreasing the anabolism of the chondrocytes [3].
Rhein (10−5M) enhanced by 46.5% of aggrecan and 50% of
prostaglandin E
2
, while it reduced by 17–30% of interleukin-
6 (IL-6), matrix metalloproteinase (MMP)-3, nitric oxide
(NO), and macrophage inflammatory protein-1𝛽 in human
osteoarthritic chondrocytes incubated with 10−10M IL-1𝛽
[21]. Rhein markedly decreased IL-1 converting enzyme
protein production [3] and partially increased tissue inhibitor
of metalloproteinase-1 (TIMP-1) synthesis and NO produc-
tion of IL-1𝛽 [22, 23]. Moreover, rhein slightly decreased
monocyte chemotactic protein-1 (MCP-1) production, while
it increased the levels of IL-1 receptor antagonist (IL-1RA),
cytokine receptors IL-6R, soluble tumor necrosis factor
(sTNF) R I and R II, and some chemokines or inter-
cellular adhesion molecule (ICAM)-1 in IL-1 (1 ng/mL)-
stimulated chondrocytes from osteoarthritic patients [24].
Rhein (5–20mg/mL) inhibited 1,25(OH)
2
D
3
-induced osteo-
calcin release, urokinase plasminogen activator (u-PA) pro-
duction, and plasminogen activator inhibitor (PAI)-1 lev-
els but increased the levels of insulin-like growth factor-
1, prostaglandin E
2,
and cyclooxygenase-2 in human OA
primary subchondral osteoblasts [25].
IL-1 plays an important role in the OA pathogenesis.
Rhein (10−7–10−5M) notably blocked IL-1𝛽 production and
NO release stimulated by lipopolysaccharide (1 𝜇g/mL) in
human OA cartilage and synovial tissue cultures. Rhein also
reversed the inhibitory effect of lipopolysaccharide (LPS)
on cartilage 35S uptake and increased IL-1RA content in
cartilage culture media [26]. Rhein also effectively inhibited
the synthesis of IL-1𝛽 in human OA synovium, as well as
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Table 1: Summary of the in vitro and in vivo evidence for the biological activities of rhein.
Pharmacological
effect In vitro evidence In vivo evidence
Hepatoprotective
activity [2, 7, 10–12]
It modulates cytochrome P450 enzymes, protects
hepatocyte from injury and prevents the progress of
hepatic fibrosis in rats, alleviates glucose and lipid
metabolism, increases energy expenditure, and
restrains proinflammatory cytokine expression in mice.
Nephroprotective
activity [15–20]
It abolishes the 𝛼-smooth muscle actin (𝛼-SMA) and
fibronectin expression of NRK-49F cells.
It alleviates renal fibrosis in mice. It reduces intestinal
permeability and protects the intestinal mucosa in
immune globulin A nephropathy (IgAN), halts the
progression of IgAN, prevents the development of
glomerulosclerosis, improves renal function, reduces
renal fibrosis and interstitial inflammation, and inhibits
the hypertrophy of renal proximal tubular epithelial
cells in rats.
Chondroprotective
activity
[3, 21, 25, 26, 28–35]
It inhibits cytokines (IL-1𝛽, LPS, TNF-𝛼, and
rhIL-1𝛼)-induced effects in human osteoarthritic (OA)
chondrocytes, human chondrosarcoma cell line
HEM-C55, human OA cartilage and synovial tissue
cultures, human umbilical vein endothelial cells
(HUVECs), and bovine and rabbit articular
chondrocytes. In particular, it stimulates aggrecan
production, promotes matrix formation, decreases the
production of certain proinflammatory mediators
(IL-1𝛽, IL-6, IL-8, and prostaglandin E2), corrects the
matrix metalloproteinases/metalloproteinases
imbalance, decreases IL-1 converting enzyme protein
production, inhibits proliferation of synoviocytes and
chondrocytes, and suppresses cathepsin B activity and
proteoglycan release.
Anti-inflammatory
activity [36, 37]
It reduces the transcription and expression of
endothelial cell adhesion molecules.
It inhibits nicotinamide adenine dinucleotide
phosphate oxidase (p22phox gp91phox) and cytokines
(matrix metalloproteinase-2, activating transcript factor
6, and p66Shc).
Antioxidant activity
[38–41]
Antioxidant properties in human peripheral
neutrophils, HUVECs, and beef heart
submitochondrial particles.
It prevents the drug-induced oxidative damage in rats.
Anticancer activity
[6–9, 42–52]
Anticarcinogenic effects in mouse epidermal cell JB6
line, human colon adenocarcinoma cells (Caco-2),
human nasopharyngeal carcinoma (NPC) cells,
HUVECs, and tongue cancer SCC-4 cells induce
apoptosis in human hepatocellular carcinoma
BEL-7402 cells, human cervical cancer Ca Ski cells,
human promyelocytic leukemia cells (HL-60), human
NPC cells, human tongue cancer cell line (SCC-4),
human hepatoblastomaG2 (HepG2) cells, KB cells, and
A-549 human lung cancer cells.
Antidiabetic activity
[4, 53–62]
It inhibits transforming growth factor 𝛽
1
and/or
glucose transporter 1 overexpression in human and rat
mesangial cells, inhibits glucose uptake in Ehrlich
ascites tumor cells and human glomerular mesangial
cells, and enhances glucose tolerance in 3T3-L1
adipocytes.
It decreases glucose concentrations, increases insulin
secretion, and/or improves glucose tolerance in db/db
mice.
Antimicrobial
activity [63, 64]
Antimicrobial effects against bacterium Helicobacter
pylori and staphylococcus aureus (S. aureus).
Purgative activity
[49, 65, 66]
It induces ion secretion in human CaCo-2 monolayer
cells and stimulates electrogenic chloride secretion in
guinea pig colon.
It increases Na+ and H2O flow in rat colon in-situ.
Lipid-lowering
activity [67, 68]
It regulates cholesterol homeostasis and lipid and
energy metabolism in 3T3-L1 and HepG2 cells. It protects against obesity in mice.
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the action of this cytokine on the cartilage, by reducing the
content of chondrocyte IL-1 receptors [27].
Rhein (10−5M) had a weak action on 𝛼4/𝛽1 or 𝛼5/𝛽1
receptors in TNF-𝛼 or recombinant human IL-1𝛼- (rhIL-
1𝛼-) stimulated chondrocytes (human chondrosarcoma cell
line HEM-C55) [28]. Rhein was found to downregulate the
proliferation rate of both synoviocytes and chondrocytes,
decrease caspase-3/7 activities, and increase the expression of
p21 and/or p27, but not cyclin D1 [29].
After bovine articular chondrocytes were cultured in
low oxygen tension with rhein (10−5M) for 24 h, IL-
1𝛽 (10 ng/mL)-activated mitogen activated protein kinase
(MAPK) pathway, DNA binding of NF-𝜅B, and activator
protein-1 (AP-1) were inhibited significantly. NF-𝜅B and AP-
1 are two key factors related to the expression of several
proinflammatory genes in chondrocytes. Furthermore, rhein
could prevent the procatabolic action of the cytokine by
inhibition of the collagenase synthesis and increase the
synthesis of matrix components, such as type II collagen
and aggrecan, which might be the mechanism of its disease-
modifying effect in OA [30]. Rhein (10−4M) evidently
prevented increases of MMPs and aggrecanase-1, NF-𝜅B,
and AP-1 DNA binding, phosphorylation of extracellular
signal-regulated protein kinase (ERK), and c-Jun NH2-
terminal kinase in bovine chondrocytes stimulated by IL-1𝛽
(10 ng/mL) in vitro [31]. Rhein dose-dependently inhibited
IL-1𝛽-induced degradation of the inhibitor 𝜅B-𝛼 protein,
translocation of the protein p65 (amember of theNF-𝜅B fam-
ily) to the nucleus, and NF-𝜅B binding to a specific (gamma-
(32)P)-labelled oligonucleotide probe. Rhein also inhibited
inducible NO synthase mRNA and protein synthesis and
NO production in a dose-dependent manner [32]. In cul-
tured rabbit articular chondrocytes, rhein (0.1–30𝜇M) dose-
dependently suppressed the rhIL-1𝛼-induced proteoglycan
degradation,MMPs activity, and the expression of proMMPs-
1, -3, -9, and -13, while it increased the production of TIMP-1
[33, 34]. Rhein at 20𝜇M inhibited the activity of cathepsin
B from human liver. In cultured rabbit cartilage challenged
with IL-1𝛽, rhein at 100 𝜇M suppressed cathepsin B activity
and proteoglycan release. After treatment with oral diacerein,
the prodrug of rhein, at the dose of 25mg/day for 3 months,
the progression of OA lesions and osteophyte formation were
restrained in the experimental OA rabbit model [35].
2.4. Anti-Inflammatory Activity. Reducing the expression of
endothelial cell adhesion molecules (ECAMs) is known to
decrease inflammation-induced vascular complications. The
transcription and expression of ECAMs, including ICAM-
1, vascular cell adhesion molecule-1 (VCAM-1), and E-
SELECTIN, could be reduced by the rhein treatment (10 and
20𝜇M) in human umbilical vein endothelial cells (HUVECs).
In the presence of LPS stimulation, the transcription and
expression of VCAM-1 were also inhibited by treatment with
rhein (10 and 20 𝜇M) [36].
Adjuvant injection elicited the inflammatory edema in
rat paw, accompanied by activation of nicotinamide ade-
nine dinucleotide phosphate (NADPH) oxidase (p22phox
gp91phox), transcript factor 6 (ATF6) and p66Shc, elevation
of cytokines including MMP-2, and an increase of the p-
Akt/Akt ration, which were notably reversed by rhein [37].
Rhein (20𝜇M) almost completely inhibited intersegmental
blood vessels formation at both 48 and 72 h after fertilization
(hpf) and completely prevented subintestinal vessel plexus
formation at 72 hpf in wild type zebra fish embryos. Rhein
affected multiple molecular targets related to angiogenesis,
particularly angpt2 and tie2, and also blocked endothelial cell
migration [69].
2.5. Antioxidant Activity. The superabundant production
of reactive oxygen species (ROS) is involved in many
pathophysiological processes such as aging, atherosclero-
sis, cancer, neurodegenerative disorders, chronic inflam-
mation, and degenerative rheumatic disease. Rhein was
observed to inhibit the ROS production in human periph-
eral neutrophils activated by N-formyl-methionyl-leucyl-
phenylalanine or phorbol-12-myristate-13-acetate in vitro
[38]. Besides, many other mechanisms of the antioxidant
effect of rhein have been revealed. Pretreatment with differ-
ent rhein concentrations (2, 4, 8, and 16 𝜇M) significantly
downregulated the mRNA expression of Bid, caspase-3,
-8, and -9 and the content of MDA and lactate dehy-
drogenase, while it increased NO content and activities
of NO synthase, SOD, and glutathione peroxidase (GSH-
PX) in hydrogen peroxide- (H
2
O
2−
) insulted HUVECs,
reversing H
2
O
2
-induced cell apoptosis [39]. Rhein dramat-
ically decreased acetaminophen-induced serum glutamate-
pyruvate transaminase, glutamate-oxaloacetic transaminase,
creatinine and urea nitrogen levels in the liver, ROS produc-
tion, NO andMDA levels, andGSH concentration in the liver
and kidney of rats. Rhein also significantly ameliorated the
histopathological damage of the liver and kidney [40]. Rhein
eliminated the biphasicity of ubiquinone oxidoreductase-
(NADH-) induced reaction and caused a substantial stim-
ulation of NADH-induced lipid peroxidation in beef heart
submitochondrial particles. Furthermore, rhein facilitated
both NADH- and NADPH-induced lipid peroxidation [41].
2.6. Anticancer Activity. Anticarcinogenic effects of rhein
on proliferation and metastasis in cells have been inves-
tigated in vitro. Rhein inhibited hypertrophic scar fibrob-
lasts proliferation in a dose-dependent manner [70]. Rhein
also dose-dependently inhibited 12-O-tetradecanoylphorbol-
13-acetate- (TPA-) induced cell transformation and AP-1
activation, prevented the phosphorylation of c-Jun protein
and c-Jun NH2-terminal kinase (JNK), did not restrain the
phosphorylation of ERK and p38 kinase in mouse epider-
mal cell JB6 line [42]. Rhein (0.1 and 1mg/mL) evidently
suppressed cell proliferation and mitogen-activated protein
(MAP) kinase activation in human colon adenocarcinoma
cells (Caco-2) but significantly lessened H
2
O
2
-induced DNA
damage and the elevated MDA and ROS levels induced by
H
2
O
2
/Fe2+ at the concentrations of 0.1–10mg/mL [43].
Cancer invasion is believed to be dependent on extra-
cellular matrix remodeling elicited by tumor cells. Rhein
inhibited invasion and migration in human nasopharyn-
geal carcinoma (NPC) cells through downregulation of
the expression of MMP-9, vascular endothelial growth
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factor (VEGF), growth factor receptor bound protein 2,
son of sevenless-1 and Ras, inhibition of the phosphoryla-
tion of ERK, p38 MAPK, and activation of transcription
factor NF-𝜅B [6]. Rhein prevented HUVEC tube forma-
tion, proliferation, and migration stimulated by vascular
endothelial growth factor (VEGF
165
) under normoxic and
hypoxic conditions. Moreover, rhein inhibited the activation
of phosphatidylinositol 3-kinase (PI3K), phosphorylated-
AKT (p-AKT), and phosphorylated ERK, suppressing in
vitro angiogenesis. Rhein restrained cell cycle and viability
of hormone-dependent breast cancer cells (MCF-7) and
hormone-independent breast cancer cells (MDA-MB-435s)
under normoxic or hypoxic conditions. In addition, rhein
decreased the expression of hypoxia-inducible factor (HIF)-
1𝛼, VEGF
165
, epidermal growth factor (EGF), the phospho-
rylation of NF-𝜅B inhibitor, and the activity of heat shock
protein 90𝛼 (Hsp90𝛼) under normoxic or hypoxic conditions
[44].
Rhein prevented themRNA expression ofMMP-9, which
plays an important role and is the most associated with
tumor invasion and metastasis in various human cancers,
decreased the levels of MMP-2 and urokinase u-PA, and
inhibited themigration and invasion in human tongue cancer
SCC-4 cells [7]. A further study demonstrated that rhein
dose-dependently induced DNA damage in SCC-4 cells,
followed by the inhibition of the mRNA expression of DNA
repair-associated O (6)-methylguanine-DNA methyltrans-
ferase (MGMT) [45].Themitosiswas inhibited inAllium cepa
root tips incubated with rhein in a dose-dependent manner
[71].
Apoptosis, a physiological process for eliminating malig-
nant cells including cancer cells, does not result in the damage
to normal cells or surrounding tissues. Rhein-induced apop-
tosis has been reported in various human cancer cells. Incu-
bation of human hepatocellular carcinoma BEL-7402 cells
with rhein at 50–200𝜇M for 48 hours caused an increasing
apoptosis, the features of which included cellular morpho-
logical change and chromatin condensation. Additionally,
rhein induced cell cycle S-phase arrest, decreased c-Myc
gene expression, and increased caspase-3 gene expression [8].
Rhein induced the abrogation of mitochondrial membrane
potential and cleavage of Bid protein in human cervical
cancer Ca Ski cells. Rhein decreased the level of Bcl-2 while
increased the levels of Fas, p53, p21, Bax, and cytoplasmic
Ca2+ and the activities of both caspase-8 and -9, promoted
caspase-3 activation, and resulted in DNA fragmentation
[46].
Rhein induced apoptosis in human promyelocytic leu-
kemia cells (HL-60) through facilitating the loss ofmitochon-
drial membrane potential, cytochrome c release from mito-
chondrion to cytosol, and cleavage of Bid protein. Rhein also
increased the generation of ROS and the phosphorylation of
c-Jun N-terminal kinase and p38 kinase [47]. Rhein elevated
nuclear condensation and DNA fragmentation, resulting in
apoptosis of human NPC cells. Furthermore, rhein increased
the activation of caspase-3, -8, -9, and -12 as well as the
levels of glucose-regulated protein 78 (GRP 78), PKR-like ER
kinase, ATF6, and CCAAT, induced the rapid accumulation
of calcium (Ca2+), and lessened themitochondrialmembrane
potential. Then Cytochrome c and apoptosis-inducing factor
were released [48].
Incubation of humanCaCo-2monolayer cells with 50𝜇M
rhein induced nitrate production and a time-dependent
polymorphonuclear leukocytes chemotaxis. Overnight rhein
incubation produced an increasing number of apoptotic
cells in the culture supernatant [49]. The treatment with
30 𝜇M rhein for 24 h showed the most efficient apoptosis
induction in SCC-4 cells. Rhein inhibited p53, cyclin A and
E, resulting in S-phase arrest of the cells.The ratio of Bax/Bcl-
2 was changed by rhein through inhibition of Bcl-2 level.
Rhein increased ROS production and Ca2+ release, decreased
the mitochondrial membrane potential level, and activated
caspase-3, -8, and -9 [50]. Rhein significantly increased the
protein expression of p53 and p21/WAF1 and the levels of
CD95 and its two forms of ligands, membrane-bound CD95
ligand and solubleCD95 ligand, in humanhepatoblastomaG2
(HepG2) cells, which not only inhibited HepG2 cell growth
but also induced cell apoptosis [51]. The IC
50
values of rhein
forKB, hepatomaBEL-7402, andmammary carcinomaMCF-
7 cells were 11.5, 14.0, and 18.4mg/mL, respectively. InKB cells
treated with rhein for 96 h, the increase of 71% was observed
in apoptotic cells [52]. The apoptosis was observed when A-
549 human lung cancer cells were incubated with rhein at
50 𝜇M for 12 h and up to 72 h. Rhein induced G
0
/G
1
arrest
through inhibition of cyclin D3, Cdk4, and Cdk6. Rhein
promotedROS andCa2+ production, capase-3 activation, and
cytochrome c release frommitochondria, increased the levels
of GADD153 and GRP78, both hallmarks of endoplasmic
reticulum stress, induced the loss of mitochondrial mem-
brane potential (ΔΨm), and led to apoptosis in A-549 human
lung cancer cells. Rhein also increased the levels of p53, p21,
and Bax, while it reduced the level of Bcl-2 [9].
2.7. Antidiabetic Activity. In vivo (in db/dbmice), a significant
decrease in area under curve (AUC) of glucose concentra-
tions, simultaneously, and increases in AUC of insulin level
and first-phase insulin secretion were observed after admin-
istration of rhein (120mg/kg) for 8weeks. Furthermore, rhein
treatment greatly protected 𝛽 cell mass and inhibited 𝛽 cell
apoptosis [53, 54]. Oral administration of rhein (120mg/kg)
for 8 or 16 weeks notably reduced fasting blood glucose
level and improved glucose tolerance. After localized at 𝛽-
cell mitochondria, rhein could protect mitochondrial ultra-
structure from hyperglycemia-inducedmitochondrial fission
protein dynamin-related protein 1 expression, resulting in
inhibition of 𝛽-cell apoptosis [55]. Intragastric treatment
with rhein (120mg/kg) significantly downregulated blood
glucose concentrations at 0, 30, 60, and 120min after glucose
load, suppressed pancreatic 𝛽-cell apoptosis, and elevated the
early-phase insulin secretion inmice, suggesting the potential
of rhein as a novel therapeutic agent for type 2 diabetes [4].
Rhein decreased urinary albumin excretion, extracellular
matrix level, and TGF-𝛽
1
and FN expression in renal tissue
and also reduced the plasma levels of cholesterol, triglyceride,
low-density lipoprotein cholesterol (LDL-C), and ApoE in
db/db mice with diabetic nephropathy (DN) [72]. In rat
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mesangial cells transfected with human glucose transporter
1 (GLUT 1) gene, rhein dose-dependently decreased 2-
deoxyglucose uptake, reversed cell hypertrophy, and lowered
the enhanced glutamine: fructose-6-phosphate aminotrans-
ferase activity of the human GLUT 1 gene, suggesting an
inhibitory effect on the GLUT 1 overexpression in diabetic
nephropathy [56].
It was observed that rhein significantly lowered the
secretion of FN and inhibited the proliferation of human
mesangial cells in mimic hyperglycemic environment of dia-
betic nephropathy, the possible mechanism of which might
be related to suppression of the bioactivities of TGF-𝛽1 and
p38MAPK [57]. TGF-𝛽
1
stimulates the glucose uptake by
enhancing the GLUT 1mRNA expression in both human and
rat glomerular mesangial cells, which could be antagonized
by rhein [58, 59].
Rhein strongly inhibited the uptake of both 2-deo-
xyglucose and 3-O-methylglucose in Ehrlich ascites tumor
cells by alteration of membrane-associated functions
[60]. In addition, rhein greatly decreased the induction
of ROS in both the NIT-1 cells and isolated islets. Rhein
enhanced insulin-stimulated glucose uptake in 3T3-L1
adipocytes, while it decreased triglyceride accumulation in
streptozotocin-induced diabetic mice [61]. Rhein markedly
attenuated the increased glucose uptake and GLUT1 mRNA
expression stimulated by TGF-𝛽
1
in a dose-dependent
manner in human glomerular mesangial cells [62]. Rhein
reversed the abnormal changes of MMP-9/TIMP-1 ratio and
impeded overexpression of integrin-linked kinase in high
glucose-induced epithelial-mesenchymal transition of HK-2
cells [73].
2.8. Antimicrobial Activity. Like many herbal monomer,
rhein has a potential antibacterial property. For example,
rhein inhibited Arylamine N-acetyltransferase activity and
growth in the bacterium Helicobacter pylori from peptic
ulcer patients [63]. In the other in vitro study, rhein showed
a good antibacterial activity against all 21 tested staphylo-
coccus aureus (S. aureus) strains. 28 transporter genes of S.
aureus ATCC25923 were differentially regulated by rhein. In
particular, rhein increased the transcription of genes (srtB
and isdABCDEFGI) encoding iron-regulated surface deter-
minants system and genes (nrdIEF and nrdDG) involved
in ribonucleotide reductase systems, while it prevented the
transcription of genes (pflAB, nirBDR, narGH, Idh1, COL-
SA0660, COL-SA2363, and COL-SA2386) responsible for
anaerobic respiration and fermentation [64].
Bacterial DNA/CpGDNA is recognized as a keymolecule
during the pathogenesis of sepsis.Therefore, preventing CpG
DNA from binding to its receptor is considered as the most
promising strategy. Rhein was demonstrated to have high
affinity for CpG DNA. It could significantly reduce CpG
DNA- and LPS-induced TNF-𝛼 release in RAW264.7 cells
[74].
2.9. Purgative Activity. Rhein (4 × 10−3M) reduced net H
2
O
andNa+ absorption in rat colon in-situ. However, its secretory
effect was associated with neither inhibition of Na+ and K+-
ATPase nor damage of the colon epithelium [65]. Mucosal
or serosal application of rhein (10 nM–0.5mM) activated
chloride secretion by excitation of submucosal neurons and
release of acetylcholine and endogenous prostaglandins [66].
In addition, rhein induced ion secretion in human CaCo-2
monolayer cells [49].
2.10. Lipid-Lowering Activity. LXRs play important roles in
regulating cholesterol homeostasis and lipid and energy
metabolism. After bounding directly to LXRs in C57BL/6J
mice fed a HF diet, rhein suppressed the expression lev-
els of LXR target genes in both 3T3-L1 and HepG2 cells
in vitro. In white adipose tissue, muscle, and liver, rhein
reprogrammed the expression of LXR target genes related
to adipogenesis and cholesterol metabolism. Rhein acti-
vated uncoupling protein 1 (UCP1) expression in brown
adipose tissue (BAT) in wild-type mice, suggesting that
rhein may protect against obesity and related metabolic
disorders through LXR antagonism and regulation of UCP1
expression in BAT [67]. Rhein downregulated the mRNA
levels of adipogenesis-specific transcription factors PPAR𝛾
and C/EBP𝛼 and their downstream target genes involved in
adipocyte differentiation, such as CD36, AP-2, and acyl CoA
oxidase in both 3T3-L1 preadipocytes and C57BL/6 mice.
Furthermore, the expression of C/EBP𝛽was reduced by rhein
in 3T3-L1 preadipocytes. HF diet-induced weight gain and
adiposity were reversed by rhein in C57BL/6 mice [68].
2.11. Other Activities. Rhein was found to have estrogenic
activity and the EC
50
value was 18.96 𝜇g/mL in the yeast-
based estrogenicity assay system [75]. LIGHT is known to
act as a novel mediator for atherogenesis. Rhein inhibited
LIGHT-induced human monocyte migration, ROS genera-
tion, the expression of chemokine receptor (CCR)1, CCR2,
and ICAM-1, the production of IL-8, MCP-1, TNF-𝛼, and
IL-6, and the activation of the p38 MAPK and NF-𝜅B [76].
Vascular smooth-muscle cell proliferation plays an important
role in atherosclerosis and restenosis. Treatment with rhein
resulted in the induction of apoptosis, release of cytochrome
c into the cytosol, loss of mitochondrial membrane potential,
decrease in Bcl-2 and Bcl-xL, and the increase in Bax and Bak
expression in TNF-𝛼-induced human aortic smooth-muscle
cells (HASMCs), thus inhibiting the proliferation of these
cells [5].
Rhein had a potent (>76%) inhibitory effect on mast-
cell degranulation in rats at a 5mg/kg dose and suppressed
lipoxygenase (LOX) enzyme activity with the IC
50
value
of 3.9 𝜇g/mL, proposing that rhein has antiallergic activity
[77]. Rhein dose-dependently blocked the increase of PAI-1
mRNA expression and protein production and inhibited the
activity of phosphor-p44/p42 MAP kinase induced by TGF-
𝛽
1
in human endothelial cells, suggesting the protective effect
on the endothelial dysfunction. Rhein might be a potential
agent for the treatment of vascular diseases [78]. Further-
more, rhein inhibited IL-1-induced secretion of MMPs and
aggrecanases and apoptosis in intervertebral disc cells, which
prevented the progression of intervertebral disc degeneration
[79].
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3. Conclusion
As reviewed here, different pharmacological experiments in
a number of in vitro and in vivo models have convincingly
demonstrated the abilities of rhein to exhibit hepatoprotec-
tive, nephroprotective, anti-inflammatory, antioxidant, anti-
cancer, and antimicrobial activities, lending support to the
rationale behind several of its potential medicinal uses.
However, further studies need to be carried out in order
to explore the concealed areas. Although various bioactivities
of rhein are substantiated by using laboratory animal or
cell models, the molecular mechanisms and targets involved
are still unknown, which will count against further clinical
applications of this agent.
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